DelAQUA Pharmaceuticals, Inc.

10:00 AM - 10:15 AM (EST), Monday, February 6, 2023 ・ Palace
DelAQUA is an early stage company developing a novel polymer platform and late stage preclinical products to provide unprecedented drug solubilization capacity and bioactivity for a wide range of hydrophobic drugs. Our technology uses a non-PEG, stealth, hyper-loaded polymeric micelle approach that dramatically enhances the solubility and stability of drugs and drug candidates by 10,000-100,000x, thereby enhancing their efficacy and safety and widening the therapeutic window.
Company Type:
Privately Funded Company
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Nanomicellar paclitaxel
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
President and Chief Technology Officer
DelAQUA Pharmaceuticals